Sigilon Therapeutics to Present at Upcoming January Conferences

News Releases  |  January 4th, 2018

CAMBRIDGE, Mass., Jan. 2, 2018 /PRNewswire/ — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced the company will present at the following conferences in January. Presentation details are as follows:

Biotech Showcase 2018


Paul Wotton, Ph.D., Chief Executive Officer


Monday, Jan. 8, 2018


1:45 p.m. PST


Room Franciscan C, Hilton San Francisco Union Square Hotel

Cell & Gene Therapy World 2018


David Peritt, Ph.D., Chief Technology Officer


Wednesday, Jan. 24, 2018


2:35 p.m. EST


Hyatt Regency Miami

About Sigilon Therapeutics

Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics’ Afibromer™ technology platform include cell implants that act as responsive “living therapeutics,” providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.

In addition to Flagship Pioneering, Sigilon Therapeutics’ co-founders include Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology Institute of Medical Engineering and Science, Department of Chemical Engineering and Koch Institute; Omid Veiseh, Ph.D., of Rice University; José Oberholzer, M.D., of the University of Virginia; and Arturo Vegas, Ph.D., of Boston University.

For more information please visit or follow on Twitter at

SOURCE Sigilon Therapeutics

Related Links


Read More